AMENDMENTS TO THE CLAIMS

Please amend claims 7 and 13 and add new claim 28 as indicated in the listing of claims set forth below. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims

1. (previously presented) A pharmaceutical preparation, comprising:

(a) a chemotherapeutic agent selected from the group consisting of: paclitaxel, aromatase inhibitors and TNF-related apoptosis inducing ligand; and

(b) 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.

2-4. (cancelled)

5. (previously presented) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is paclitaxel.

6. (original) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is TNF-related apoptosis inducing ligand.

7. (currently amended) A method of treating a patient suffering from breast cancer according to claim 28 comprising administering to the patient an effective amount of a chemotherapeutic agent selected from the group consisting of paclitaxel and letrozole; followed sequentially by an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof.

8-10. (cancelled)

11. (original) A method according to claim 7 wherein the chemotherapeutic agent is paclitaxel.

12. (previously presented) A method according to claim 7 wherein the chemotherapeutic agent is letrozole.

13. (currently amended) A method of treating a patient suffering from breast cancer according to claim 28 comprising administering to the patient an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof, followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.

14-25. (cancelled)

26. (previously presented) A commercial package comprising a unit dosage form of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof, and a unit dosage form of a chemotherapeutic agent selected from the group consisting of: paclitaxel, aromatase inhibitors and TNF-related apoptosis inducing ligand; together with instructions for administering sequential unit doses of said chemotherapeutic agent and said 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or pharmaceutically acceptable salt thereof for the treatment of breast cancer.

27. (previously presented) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is an aromatase inhibitor wherein the aromatase inhibitor is letrozole.

28. (new) A method of treating a patient suffering from breast cancer comprising administering to the patient an effective amount of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof, wherein the administration of 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or pharmaceutically acceptable salt thereof, is preceded sequentially by a chemotherapeutic agent selected from the group consisting of paclitaxel and letrozole, or followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.